Business Description
IDT Australia Ltd
NAICS : 325412
SIC : 2834
ISIN : AU000000IDT0
Description
IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.81 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.33 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 3.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -21.6 | |||||
| 3-Year EPS without NRI Growth Rate | -89.5 | |||||
| 3-Year FCF Growth Rate | -45.7 | |||||
| 3-Year Book Growth Rate | -6.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 56.73 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.52 | |||||
| 9-Day RSI | 43.78 | |||||
| 14-Day RSI | 46.08 | |||||
| 6-1 Month Momentum % | 37.99 | |||||
| 12-1 Month Momentum % | 91.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.24 | |||||
| Quick Ratio | 2.81 | |||||
| Cash Ratio | 1.29 | |||||
| Days Inventory | 169.95 | |||||
| Days Sales Outstanding | 84.27 | |||||
| Days Payable | 215.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.4 | |||||
| Shareholder Yield % | -8.38 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.15 | |||||
| Operating Margin % | -76.37 | |||||
| Net Margin % | -63.79 | |||||
| FCF Margin % | -86.15 | |||||
| ROE % | -27.66 | |||||
| ROA % | -23.47 | |||||
| ROIC % | -30.64 | |||||
| ROC (Joel Greenblatt) % | -37.97 | |||||
| ROCE % | -31.82 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 15 | |||||
| PS Ratio | 3.53 | |||||
| PB Ratio | 1.88 | |||||
| Price-to-Tangible-Book | 1.92 | |||||
| EV-to-EBIT | -5.98 | |||||
| EV-to-EBITDA | -6.77 | |||||
| EV-to-Revenue | 4.57 | |||||
| EV-to-FCF | -5.3 | |||||
| Price-to-Median-PS-Value | 1.64 | |||||
| Price-to-Net-Current-Asset-Value | 11.5 | |||||
| Earnings Yield (Greenblatt) % | -16.72 | |||||
| FCF Yield % | -20.41 | |||||
| Forward Rate of Return (Yacktman) % | 70.1 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers